Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Organogenesis Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical & sports medicine markets. Their products aim to empower healing and restore normal function by harnessing the inherent healing potential of the body. Organogenesis offers a portfolio of bioactive and acellular biomaterials products in wound care and surgical biologics, including orthopedics and spine. The company is committed to advancing medical technology and improving patient outcomes through innovative therapies.
The Canton headquarters serves as the primary hub for corporate operations, research and development, manufacturing, and strategic decision-making for Organogenesis.
The Canton facility includes state-of-the-art research laboratories, advanced manufacturing capabilities for regenerative medicine products, and corporate offices. It is designed to support the complex processes involved in developing and producing living-cell-based therapies.
The work culture at Organogenesis's headquarters is often described as innovative, patient-focused, and collaborative. Employees are typically driven by the mission to improve patient lives through regenerative medicine. There's an emphasis on scientific rigor and quality.
This location is significant as it centralizes key functions, fostering synergy between R&D, manufacturing, and corporate strategy. Its proximity to Boston's rich biotech ecosystem provides access to talent, research collaborations, and industry expertise.
Organogenesis primarily operates and markets its products within the United States. While its physical office and manufacturing locations are U.S.-based, its products impact patients across the country. The company may engage in international distribution through partnerships or direct sales in select markets, but its core strategic focus has historically been the U.S. healthcare system.
25 Dan Road
Canton
MA
USA
Address: 10655 Sorrento Valley Road, San Diego, CA 92121, USA
Supports West Coast operations and leverages the biotech hub of San Diego for talent and research. Specializes in tissue-based product development and manufacturing.
Address: 4888 Valleydale Road, Birmingham, AL 35242, USA
Strengthens operational capabilities in the Southeastern U.S. and supports the distribution network for its tissue-based products.
Address: 20271 Goldenrod Lane, Germantown, MD 20876, USA
Enhances the company's capabilities in collagen-based product development and manufacturing, leveraging the Mid-Atlantic biotech corridor.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Organogenesis' leadership includes:
Organogenesis has been backed by several prominent investors over the years, including:
In the past 12-18 months, Organogenesis has seen some stability in its core executive team. Key appointments often focus on strengthening commercial operations and R&D leadership. Publicly available information suggests no major C-suite upheavals recently, but ongoing strategic roles may see adjustments.
Discover the tools Organogenesis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Organogenesis commonly uses the email format of first initial followed by last name. This is a prevalent structure in many corporations. Variations might exist but this is the most likely primary format.
[first_initial][last]@organogenesis.com
Format
jdoe@organogenesis.com
Example
85%
Success rate
Yahoo Finance • May 9, 2024
Organogenesis (ORGO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago. The company posted revenues of $90.29 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 5.95%....more
GlobeNewswire • March 7, 2024
Organogenesis reported net revenue of $109.3 million for Q4 2023, a decrease of 5% year-over-year. For fiscal year 2023, net revenue was $433.3 million, a decrease of 4% compared to 2022. The company provided financial guidance for fiscal year 2024....more
Business Wire • February 21, 2024
Organogenesis announced the presentation of new clinical data on PuraPly® AM at the 2024 Diabetic Foot Global Conference (DFCon). The data highlighted PuraPly AM's effectiveness in treating complex diabetic foot ulcers....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Organogenesis, are just a search away.